Impact of COVID-19 in allergen immunotherapy: An Italian survey
-
Published:2022-09-01
Issue:5
Volume:50
Page:57-60
-
ISSN:0301-0546
-
Container-title:Allergologia et Immunopathologia
-
language:
-
Short-container-title:Allergol Immunopathol
Author:
Sánchez-López JaimeORCID,
Heffler EnricoORCID,
Canonica Giorgio WalterORCID
Abstract
Allergen immunotherapy (AIT) is a common treatment for patients with allergic asthma and allergic rhinoconjunctivitis. There is evidence that the COVID-19 pandemic could have altered the administration of AIT in patients in some countries, as the pandemic caused major limitations to healthcare access and delivery. The objective of this study was to evaluate the impact of the disruption imposed by the pandemic on the perceptions and administration of AIT therapies in Italy. An online survey was carried out among Italian allergists between 22 February 2021 and 12 April 2021. The results show that Italian physicians (N=66) did not consider that the COVID-19 pandemic presented an added risk to patients with allergic asthma or rhinitis receiving AIT. Although most treatments continued, there were reduced rates of AIT therapy initiations and sublingual AIT was favored over subcutaneous AIT.
Publisher
Codon Publications
Subject
General Medicine,Immunology and Allergy,Immunology,Pulmonary and Respiratory Medicine